The impairment of induction chemotherapy for stage II nasopharyngeal carcinoma treated with intensity‐modulated radiotherapy with or without concurrent chemotherapy: A propensity score‐matched analysis-Reference-Cited by-同舟云学术

The impairment of induction chemotherapy for stage II nasopharyngeal carcinoma treated with intensity‐modulated radiotherapy with or without concurrent chemotherapy: A propensity score‐matched analysis

Published:2022-09-17 Issue:3 Volume:12 Page:2970-2978
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Lai YuLin¹,Wang ChengTao¹,Yang XingLi²,He ShaSha¹,Wang Yan¹,Chen Yong¹^ORCID

Affiliation:

1. Department of Radiation Oncology, The First Affiliated Hospital Sun Yat‐sen University Guangzhou China

2. Department of Radiation Oncology, Sun Yat‐sen University Cancer Center, State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy Guangzhou People's Republic of China

Funder

National Natural Science Foundation of China

Natural Science Foundation of Guangdong Province

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.5199

Reference41 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Nasopharyngeal carcinoma

3. Analysis of Plasma Epstein–Barr Virus DNA to Screen for Nasopharyngeal Cancer

4. Role of sequential chemoradiotherapy in stage II and low-risk stage III–IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis

5. Improvement of survival after addition of induction chemotherapy to radiotherapy in patients with early-stage nasopharyngeal carcinoma: Subgroup analysis of two Phase III trials